The company has expanded substantially in the international market over the past couple of years largely through inorganic expansion. This has resulted in margin contraction from 18.6% in FY12 to 12.8% in FY15. On valuation front company is available at 27.2x its FY15EPS at higher price band of Rs.1,050. However, company has reported strong H1FY16 result performance led by better product mix & consolidation of two subsidiaries namely Cachet and Indchemie with itself. The EBITDA margins also…
IPO Note – Alkem Laboratories Ltd – Subscribe (GEPL)
| Subscribe To Our Free Newsletter |
